BRAF and melanoma: Additionally, while patients with melanomas harboring a different mutation, BRAF V600K, respond to BRAFi, they have been shown to have shorter PFS compared to BRAF V600E mutant melanomas with this therapy but exhibit superior clinical response to ICI (Akbani 2015; Pires Da Silva et al., 2019; Yang et al., 2023).